UnitedHealth raised full-year 2026 adjusted EPS guidance to at least $20.50 following improved third-quarter medical ratios and Optum Health recovery. At 16.3 times 2027 earnings, the stock fairly reflects steady margin normalization against lingering commercial cost headwinds.
Key points
- $20.50 raised adjusted earnings floor for 2026 implies UnitedHealth trades at 18.4 times guided net earnings.
- 88.4% third-quarter medical care ratio improved 150 basis points year-over-year, aided by $610 million of favorable claims development.
- $735 million of Optum Health operating earnings marked a notable turnaround from $41 million a year ago, validating clinical cost controls.
The call
UnitedHealth's current price requires modest operational stabilization and high-single-digit profit growth. At $377.91, the equity trades at 18.4 times 2026 guided adjusted earnings and 16.3 times 2027 estimates. The market is about right on 2026 execution, but it remains cautious regarding whether commercial pricing and specialty pharmacy pressures can sustain double-digit expansion.
Quarterly adjusted diluted earnings per share ($)- Reported adjusted EPS
- Analyst estimate
Source: Company reports (Form 10-K, 10-Q, 8-K) and analyst estimates for Q4 2026 through 2027.
We believe earnings will advance steadily into 2027. Optum Health margin repair and Medicare Advantage bid adjustments support 13% adjusted earnings growth to $23.17 per share next year. However, commercial membership attrition and state Medicaid reimbursement lags will keep returns moderate. A 9.8% potential return supports our Hold rating.
Operating earnings by segment ($ billions)- Q3 FY25 operating earnings
- Q3 FY26 operating earnings
Source: UnitedHealth Group Q3 2026 earnings release schedules. Eliminations are consolidated adjustments.
Valuation
| Valuation metric | 2026E | 2027E |
|---|
| Total revenue ($ billions) | $450 | $473 |
| Operating margin (%) | 6.4% | 6.7% |
| GAAP diluted EPS ($) | $19.55 | $21.90 |
| Adjusted diluted EPS ($) | $20.50 | $23.17 |
| Target forward P/E multiple | , | 17.9× |
| 12-month price target ($) | , | $415.00 |
We value UnitedHealth at 17.9 times 2027 estimated adjusted earnings of $23.17 per share, raising our 12-month price target to $415.00. This multiple reflects an established healthcare compounder navigating lingering regulatory and medical inflation headwinds. Because upside remains below our 12% threshold, we maintain a Hold rating.
Risks
- Commercial medical cost trends outpace pricing due to arbitration fees under the No Surprises Act, visible if commercial loss ratios exceed 86%.
- Optum Health margin turnaround stalls due to provider turnover, signaled by operating margins retreating below 3.0%.
- Federal risk-adjustment audits and unresolved Department of Justice antitrust inquiries produce unexpected restitution penalties in quarterly disclosures.
What would change my mind
We would upgrade to Buy if commercial medical loss ratios decisively drop below 85% while Optum Health sustains operating margins above 4.5%.